Testing citrate blood-thinning during kidney dialysis in adults
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests how safe a specific blood thinner called “citrate” is when used during continuous kidney dialysis (CRRT) for people with AKI or kidney failure. If you qualify, your care team will compare citrate safety against standard approaches to see if it’s tolerable and safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legally authorized representative) can sign an informed consent form
- You are 18 years old or older
- You have AKI or end-stage kidney disease and need continuous dialysis (CRRT)
- You have a dialysis catheter in place that your clinic normally uses
- You are not pregnant and are not breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a specific blood-thinning method using citrate works safely and effectively in critically ill patients whose kidneys have suddenly stopped working and need a special filtering machine. Researchers want to confirm that this approach prevents dangerous blood clots while keeping patients safe.
This study looks at using a blood thinner called citrate during continuous kidney dialysis (renal replacement therapy) in critically ill patients with acute kidney injury. It aims to see if this approach is safe and workable for patients whose bodies may not process citrate normally.
This trial studies whether a blood test called delta C-cistatin can help doctors predict when patients can safely stop continuous kidney dialysis after acute kidney injury.
This trial compares the usual dose of continuous dialysis with a lower dose to see if a lower dose is just as safe and effective for critically ill patients with sudden kidney failure.
This trial tests two different blood-thinning methods used during continuous kidney-support treatment (CRRT) for patients who have developed severe kidney injury due to sepsis. The goal is to see which method works better and is safer for patients in this critical condition.
This study looks at two different blood thinners—regional citrate and systemic heparin—used during continuous kidney replacement therapy (CKRT) for acute kidney injury (AKI). It aims to learn which works better and safer.
Hear when a new Acute Kidney Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.